{
    "id": 7572,
    "fullName": "ETV6 - JAK2",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ETV6-JAK2 results from the fusion of ETV6 (also referred to as TEL) and JAK2 (PMID: 9736611). ETV6-JAK2 results in growth factor independence, constitutive kinase activity and increased downstream signaling (PMID: 9736611).",
            "references": [
                {
                    "id": 3037,
                    "pubMedId": 9736611,
                    "title": "Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9736611"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2120,
        "geneSymbol": "ETV6",
        "terms": [
            "ETV6",
            "TEL",
            "TEL/ABL",
            "THC5"
        ]
    },
    "variant": "ETV6 - JAK2",
    "createDate": "06/12/2015",
    "updateDate": "06/12/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 3717,
                "geneSymbol": "JAK2",
                "terms": [
                    "JAK2",
                    "JTK10",
                    "THCYT3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 2449,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 7560,
                "profileName": "ETV6 - JAK2 JAK2 N909K"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2447,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 7562,
                "profileName": "ETV6 - JAK2 JAK2 R975G"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2448,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 7564,
                "profileName": "ETV6 - JAK2 JAK2 V881A"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5576,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21289,
                "profileName": "ETV6 - JAK2 JAK2 G831R"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5575,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21290,
                "profileName": "ETV6 - JAK2 JAK2 E864K"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5577,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21291,
                "profileName": "ETV6 - JAK2 JAK2 G935R"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5579,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21292,
                "profileName": "ETV6 - JAK2 JAK2 M929I"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5580,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21293,
                "profileName": "ETV6 - JAK2 JAK2 P1057S"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5581,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21294,
                "profileName": "ETV6 - JAK2 JAK2 R1127K"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5582,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21295,
                "profileName": "ETV6 - JAK2 JAK2 Y918H"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13069,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-JAK2 were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185).",
            "molecularProfile": {
                "id": 27216,
                "profileName": "ETV6 - JAK2"
            },
            "therapy": {
                "id": 2780,
                "therapyName": "NS-018",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2936,
                    "pubMedId": 22829185,
                    "title": "Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22829185"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21279,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pyridone 6 (CMP6) inhibited proliferation of transformed mouse Ba/F3 cells expressing ETV6-JAK2 in culture (PMID: 23471820).",
            "molecularProfile": {
                "id": 27216,
                "profileName": "ETV6 - JAK2"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17688,
                    "pubMedId": 23471820,
                    "title": "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23471820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7560,
            "profileName": "ETV6 - JAK2 JAK2 N909K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7562,
            "profileName": "ETV6 - JAK2 JAK2 R975G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7564,
            "profileName": "ETV6 - JAK2 JAK2 V881A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21289,
            "profileName": "ETV6 - JAK2 JAK2 G831R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21290,
            "profileName": "ETV6 - JAK2 JAK2 E864K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21291,
            "profileName": "ETV6 - JAK2 JAK2 G935R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21292,
            "profileName": "ETV6 - JAK2 JAK2 M929I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21293,
            "profileName": "ETV6 - JAK2 JAK2 P1057S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21294,
            "profileName": "ETV6 - JAK2 JAK2 R1127K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21295,
            "profileName": "ETV6 - JAK2 JAK2 Y918H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27216,
            "profileName": "ETV6 - JAK2",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}